Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Short chain fatty acids

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44335   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    5 result(s) found for: Short chain fatty acids. Displaying page 1 of 1.
    EudraCT Number: 2021-006814-35 Sponsor Protocol Number: MoodBugs_Rifaximin Start Date*: 2022-09-27
    Sponsor Name:KU Leuven
    Full Title: A randomized, triple-blind, placebo-controlled study on the effect of rifaximin on psychobiological functions in healthy men
    Medical condition: Experimental study with healthy participants recruited from the general population; no vulnerable individuals or clinical groups will be involved. Our objective is to test whether rifaximin adminis...
    Disease:
    Population Age: Adults Gender: Male
    Trial protocol: BE (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2021-006677-26 Sponsor Protocol Number: 68797373 Start Date*: 2022-06-22
    Sponsor Name:Maastricht University
    Full Title: Metabolic effects of ketohexokinase inhibition in individuals with non-alcoholic fatty liver disease
    Medical condition: Healthy volunteers (non-alcoholic fatty liver disease)
    Disease: Version SOC Term Classification Code Term Level
    25.0 10024581 - Lipid metabolism and deposit disorders NEC 10029530 Non-alcoholic fatty liver PT
    25.0 10024581 - Lipid metabolism and deposit disorders NEC 10082249 Nonalcoholic fatty liver disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: View results
    EudraCT Number: 2008-000046-31 Sponsor Protocol Number: Omega18-13-03 Start Date*: 2011-11-29
    Sponsor Name:The Sahlgrenska Center for Pediatric Ophtalmology Research
    Full Title: A randomised Intervention, Single-Center Study to Determine the Role of Fatty Acids in Serum in preventing Retinopathy of Prematurity
    Medical condition: Premature male/female infants, <28 gestational weeks at birth with risk of developing retinopathy of prematurity (ROP)
    Disease:
    Population Age: Preterm newborn infants, Under 18 Gender: Male, Female
    Trial protocol: SE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2012-000201-72 Sponsor Protocol Number: 1 Start Date*: 2012-05-11
    Sponsor Name:University of Aberdeen [...]
    1. University of Aberdeen
    2. University of Aberdeen
    Full Title: The Effects of Inorganic Nitrite on cardiac and skeletal muscle: Physiology, Pharmacology and Therapeutic Potential. Peripheral Arterial Disease
    Medical condition: Peripheral arterial Disease
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2017-000748-16 Sponsor Protocol Number: MT-2-01 Start Date*: 2017-09-14
    Sponsor Name:Minoryx Therapeutics S.L.
    Full Title: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTINATIONAL, MULTICENTER STUDY WITH OPEN-LABEL TREATMENT EXTENSION TO ASSESS THE EFFECT OF MIN-102 ON THE PROGRESSION OF ADRENOMYELONEUROPATHY IN M...
    Medical condition: ADRENOMYELONEUROPATHY IN MALE PATIENTS WITH X-LINKED ADRENOLEUKODYSTROPHY
    Disease:
    Population Age: Adults Gender: Male
    Trial protocol: GB (GB - no longer in EU/EEA) DE (Completed) HU (Completed) ES (Ongoing) NL (Completed) PL (Prematurely Ended) IT (Completed)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sat May 10 08:33:30 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA